Total Payments
$4,040
2024 Payments
$411.44
Companies
24
Transactions
263
Medicare Patients
9,967
Medicare Billing
$610,223
Payment Breakdown by Category
Food & Beverage$4,034 (99.8%)
Education$6.25 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $4,034 | 262 | 99.8% |
| Education | $6.25 | 1 | 0.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $845.21 | 62 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $746.02 | 49 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $438.74 | 40 | $0 (2024) |
| Amgen Inc. | $362.39 | 21 | $0 (2024) |
| PFIZER INC. | $232.79 | 17 | $0 (2024) |
| Merck Sharp & Dohme LLC | $153.93 | 8 | $0 (2023) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $151.82 | 8 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $148.13 | 8 | $0 (2023) |
| Medtronic, Inc. | $142.97 | 6 | $0 (2024) |
| Amarin Pharma Inc. | $125.76 | 9 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $411.44 | 22 | Amgen Inc. ($91.86) |
| 2023 | $643.05 | 34 | Novartis Pharmaceuticals Corporation ($138.08) |
| 2022 | $397.18 | 25 | Amgen Inc. ($119.59) |
| 2021 | $475.55 | 29 | Janssen Pharmaceuticals, Inc ($151.73) |
| 2020 | $378.37 | 27 | Janssen Pharmaceuticals, Inc ($130.71) |
| 2019 | $538.85 | 37 | Janssen Pharmaceuticals, Inc ($145.00) |
| 2018 | $475.39 | 34 | Novartis Pharmaceuticals Corporation ($134.91) |
| 2017 | $720.57 | 55 | Novartis Pharmaceuticals Corporation ($172.88) |
All Payment Transactions
263 individual payment records from CMS Open Payments — Page 1 of 11
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/10/2024 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $20.34 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 11/26/2024 | Medtronic, Inc. | INTERSTIM (Device) | Food and Beverage | In-kind items and services | $23.08 | General |
| Category: Sacral Nerve Stimulation | ||||||
| 11/26/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $14.54 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/12/2024 | PFIZER INC. | ELIQUIS (Drug) | Food and Beverage | In-kind items and services | $16.09 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 11/01/2024 | Medtronic, Inc. | INTERSTIM (Device) | Food and Beverage | In-kind items and services | $17.13 | General |
| Category: Sacral Nerve Stimulation | ||||||
| 10/30/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $16.24 | General |
| Category: Cardiology | ||||||
| 09/03/2024 | Kiniksa Pharmaceuticals International, plc | Arcalyst (Drug) | Food and Beverage | In-kind items and services | $19.75 | General |
| Category: Not Applicable | ||||||
| 08/05/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $20.10 | General |
| Category: Cardiology | ||||||
| 07/15/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $15.21 | General |
| Category: Cardiovascular | ||||||
| 06/20/2024 | Kiniksa Pharmaceuticals International, plc | Arcalyst (Drug) | Food and Beverage | In-kind items and services | $21.27 | General |
| Category: Not Applicable | ||||||
| 06/12/2024 | PFIZER INC. | ELIQUIS (Drug) | Food and Beverage | In-kind items and services | $15.29 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 06/11/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $19.27 | General |
| Category: Cardiology | ||||||
| 05/15/2024 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $15.37 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 05/14/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $15.60 | General |
| Category: Cardiology | ||||||
| 04/16/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $21.83 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 03/11/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $20.65 | General |
| Category: Cardiology | ||||||
| 03/07/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $14.33 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 02/28/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $24.85 | General |
| 02/06/2024 | Kiniksa Pharmaceuticals International, plc | Arcalyst (Drug) | Food and Beverage | In-kind items and services | $20.03 | General |
| Category: Not Applicable | ||||||
| 01/30/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $32.21 | General |
| Category: DIABETES | ||||||
| 01/24/2024 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | LifeVest (Device) | Food and Beverage | Cash or cash equivalent | $12.29 | General |
| Category: Electromedical and Electrotherapeutic Apparatus | ||||||
| 01/08/2024 | Medtronic, Inc. | INTERSTIM (Device) | Food and Beverage | In-kind items and services | $15.97 | General |
| Category: Sacral Nerve Stimulation | ||||||
| 12/18/2023 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $14.27 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/28/2023 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $26.89 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/14/2023 | Medtronic, Inc. | INTERSTIM (Device) | Food and Beverage | In-kind items and services | $59.06 | General |
| Category: Sacral Nerve Stimulation | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 24 | 2,588 | 3,430 | $560,516 | $165,876 |
| 2022 | 26 | 2,718 | 3,438 | $566,350 | $159,461 |
| 2021 | 27 | 2,428 | 3,102 | $463,072 | $150,062 |
| 2020 | 27 | 2,233 | 2,828 | $423,370 | $134,824 |
Total Patients
9,967
Total Services
12,798
Medicare Billing
$610,223
Procedure Codes
112
All Medicare Procedures & Services
112 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 394 | 584 | $119,720 | $56,368 | 47.1% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 194 | 283 | $42,450 | $18,231 | 42.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 74 | 111 | $32,190 | $15,538 | 48.3% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2023 | 231 | 233 | $106,015 | $12,590 | 11.9% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 79 | 118 | $23,600 | $11,516 | 48.8% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 440 | 721 | $57,680 | $8,079 | 14.0% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 56 | 59 | $16,225 | $6,304 | 38.9% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 112 | 112 | $50,960 | $6,293 | 12.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 42 | 42 | $11,340 | $5,340 | 47.1% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 36 | 37 | $11,100 | $5,250 | 47.3% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2023 | 492 | 632 | $18,960 | $4,046 | 21.3% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Office | 2023 | 58 | 58 | $17,400 | $3,585 | 20.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 11 | 11 | $3,905 | $2,000 | 51.2% |
| 93312 | Ultrasound of heart with probe in esophagus, with report | Facility | 2023 | 20 | 21 | $6,930 | $1,807 | 26.1% |
| 92960 | External shock to heart to regulate heart beat | Facility | 2023 | 20 | 21 | $8,190 | $1,688 | 20.6% |
| 93351 | Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | Facility | 2023 | 22 | 22 | $8,800 | $1,402 | 15.9% |
| 93016 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | Office | 2023 | 59 | 59 | $4,130 | $1,008 | 24.4% |
| 93296 | Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | Office | 2023 | 27 | 56 | $5,040 | $913.92 | 18.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 13 | 13 | $1,885 | $875.15 | 46.4% |
| 93294 | Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | Office | 2023 | 19 | 40 | $4,000 | $804.54 | 20.1% |
| 93018 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | Office | 2023 | 59 | 59 | $2,655 | $667.29 | 25.1% |
| 93244 | Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | Office | 2023 | 30 | 33 | $2,145 | $476.73 | 22.2% |
| 93242 | Heart rhythm recording continous external ekg over more than 48 hours up to 7 days | Office | 2023 | 30 | 33 | $1,386 | $328.00 | 23.7% |
| 93320 | Ultrasound of heart blood flow, valves and chambers | Facility | 2023 | 21 | 22 | $1,870 | $315.26 | 16.9% |
| 93016 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | Facility | 2023 | 14 | 14 | $980.00 | $239.12 | 24.4% |
About Dr. Eric Gejer, DO
Dr. Eric Gejer, DO is a Nuclear Cardiology healthcare provider based in Doylestown, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/01/2006. The National Provider Identifier (NPI) number assigned to this provider is 1104863067.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Eric Gejer, DO has received a total of $4,040 in payments from pharmaceutical and medical device companies, with $411.44 received in 2024. These payments were reported across 263 transactions from 24 companies. The most common payment nature is "Food and Beverage" ($4,034).
As a Medicare-enrolled provider, Gejer has provided services to 9,967 Medicare beneficiaries, totaling 12,798 services with total Medicare billing of $610,223. Data is available for 4 years (2020–2023), covering 112 distinct procedure/service records.
Ad
Practice Information
- Specialty Nuclear Cardiology
- Other Specialties Cardiovascular Disease
- Location Doylestown, PA
- Active Since 06/01/2006
- Last Updated 11/02/2023
- Taxonomy Code 207UN0901X
- Entity Type Individual
- NPI Number 1104863067
Products in Payments
- XARELTO (Drug) $746.02
- ENTRESTO (Drug) $668.99
- ELIQUIS (Drug) $561.31
- Repatha (Biological) $288.08
- LEQVIO (Drug) $176.22
- VERQUVO (Drug) $153.93
- INTERSTIM (Device) $142.97
- Vascepa (Drug) $125.76
- PRALUENT (Drug) $105.80
- FARXIGA (Drug) $98.07
- PRALUENT ALIROCUMAB INJECTION (Biological) $92.47
- JARDIANCE (Drug) $86.19
- WATCHMAN Access System (Device) $85.11
- Arcalyst (Drug) $78.53
- Corlanor (Drug) $74.31
- PRADAXA (Drug) $65.63
- CHANTIX (Drug) $59.07
- UPTRAVI (Drug) $51.10
- BRILINTA (Drug) $50.06
- BYSTOLIC (Drug) $43.01
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.